Results 21 to 30 of about 21,501 (259)

Fixed drug eruption pada perioral akibat obat golongan quinolone

Fixed drug eruption in the perioral due to quinolone medications

Jurnal Kedokteran Gigi Universitas Padjadjaran, 2018
Pendahuluan: Fixed Drug Eruption (FDE) adalah salah satu diagnosis reaksi hypersensitivitas tipe 4 yang bermanifestasi di kulit berbentuk makula merah kebiruan dan kadang-kadang bula diatasnya, serta muncul ditempat yang sama apabila terpapar obat yang ...
Nur Khamilatusy Solekhah, Rochman Mujayanto   +1 more
doaj   +1 more source

Clinical Features of Drug Eruption in An Indonesian Tertiary Hospital

Majalah Kedokteran Bandung
Drug eruption is a response to drugs undergoing sensitization, which is mediated by the immune system. Clinical features of drug eruptions, such as maculopapular drug eruption, Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), and drug ...
Enny Rohmawaty, Mochamad Devani, Miranti Pangastuti   +2 more
doaj   +1 more source

Modafinil-induced Fixed Drug Eruption

Indian Journal of Psychological Medicine, 2012
Modafinil is a stimulant drug widely used to promote wakefulness in a variety of psychiatric and neurological conditions. Modafinil-induced severe dermatologic reactions are uncommon but serious side effects.
Girish Vasant Gaikwad, Chetali Vijay Dhuri   +1 more
doaj   +1 more source

Bullous fixed drug eruption due to erlotinib: A rare case report

Annals of Oncology Research and Therapy
Fixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various ...
Kallolinee Samal, Manoj Kumar Nayak, Srigopal Mohanty, Nibedita Dixit   +3 more
doaj   +1 more source

A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ‐SAFE Study

Arthritis &Rheumatology, EarlyView.
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee, Jay J. Patel, Jessica Kent, Betty Chewning, Sancia Ferguson, Patricia Tellez‐Giron, David Gazeley, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Lichenoid drug eruption induced by chlordiazepoxide

Journal of Dermatology and Dermatologic Surgery, 2022
Lichenoid drug reaction is a cutaneous drug eruption due to a Type IV delayed hypersensitivity reaction. It usually occurs months to years following the intake of the drug and is characterized by purple, flat, polygonal papules that spread symmetrically ...
Osamah M Alkhuzaim
doaj   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed   +24 more
wiley   +1 more source

Fixed Food Eruption Caused by Cashew Nut

Allergology International, 2008
Background: The diagnosis of fixed ‘drug’ eruption is not difficult for dermatologists, but it is difficult to identify the causative agent when the patient denies ingestion of any drugs. There have been some reported cases of fixed ‘food’ eruption. Case
Satoshi Fukushima, Masato Kidou, Hironobu Ihn   +2 more
doaj   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source